[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nasal-obstruction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nasal-obstruction":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,48,86,105,141,165,193,226,251,275,297,324,355,383],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100633832","patient-reported-outcomes-and-complications-after-structural-rhinoplasty-using-septal-extension-grafts-100633832",false,"NCT07531810","Patient-Reported Outcomes and Complications After Structural Rhinoplasty Using Septal Extension Grafts","Patient-Reported Outcomes and Complications Following Structural Rhinoplasty Using Septal Extension Grafts: A Prospective Cohort Study","SEG-PROM","Inclusion Criteria:\n\n* Age 18 years or older\n* Undergoing primary structural rhinoplasty with septal extension graft\n* Able to understand and complete patient-reported outcome questionnaires (PROMs)\n* Willing to participate and provide written informed consent\n\nExclusion Criteria:\n\n* History of previous nasal surgery (revision rhinoplasty)\n* Undergoing concomitant major craniofacial procedures\n* Missing preoperative PROM data\n* Unable to complete postoperative follow-up assessments","ALL","18 Years",{"count":20,"type":21},50,"ESTIMATED","6 Months","OBSERVATIONAL","Structural rhinoplasty with septal extension graft (SEG) is commonly used to achieve stable nasal tip support and predictable long-term outcomes. However, surgical success is not limited to structural stability alone and should also be evaluated from the patient's perspective.\n\nPatient-reported outcome measures (PROMs) have gained increasing importance in rhinoplasty, as they reflect patient satisfaction and perceived nasal function. Despite the widespread use of SEG, prospective studies evaluating PROMs together with postoperative clinical findings over time remain limited.\n\nThis prospective observational cohort study aims to evaluate longitudinal changes in patient-reported outcomes and postoperative findings in adult patients undergoing primary structural rhinoplasty with SEG-based nasal tip support. Validated PROM instruments will be applied preoperatively and during routine postoperative follow-up visits at approximately 1, 3, and 6 months.\n\nIn addition, postoperative complications and revision procedures will be recorded. The study aims to provide a more comprehensive understanding of patient-centered outcomes and their relationship with clinical findings in SEG-based rhinoplasty.",[26,27,28],"Nasal Deformity","Rhinoplasty","Nasal Obstruction",[30,31,32,33,34],"Structural rhinoplasty","Septal extension graft","Patient reported outcomes","SCHNOS","Rhinoplasty outcomes","RECRUITING","2026-06-17",{"date":38,"type":39},"2026-06-22","ACTUAL",{"date":41,"type":39},"2026-04-01",{"date":43,"type":21},"2027-06",{"name":45,"class":46},"Cumhuriyet University Hospital","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":85},"100642484","phase-3-fixed-dose-combination-of-1000-mg-dipyrone-monohydrate--60-mg-caffeine--4-mg-chlorpheniramine-maleate-in-improving-symptoms-of-the-common-cold-and-flu-in-adults-100642484","NCT07626437","Fixed-dose Combination of 1000 mg Dipyrone Monohydrate + 60 mg Caffeine + 4 mg Chlorpheniramine Maleate in Improving Symptoms of the Common Cold and Flu in Adults","A Phase III, Multicenter, Double-blind, Randomized, Parallel-group Non-inferiority Clinical Trial to Evaluate the Efficacy and Safety of a Fixed-dose Combination of 1000 mg Dipyrone Monohydrate + 60 mg Caffeine + 4 mg Chlorpheniramine Maleate Compared to Benegrip® in Improving Symptoms of the Common Cold and Flu in Adult Participants","PANAMA","Inclusion Criteria:\n\n* The following criteria must be met for the participant to be included in the study:\n\n  1. Participants of both sexes, aged between 18 and 60 years.\n  2. Be able to understand, agree to participate in the study, comply with procedures, and attend visits, as indicated by signing the informed consent form (ICF) approved by the Ethics Committee.\n  3. Present symptoms of nasal obstruction and\u002For congestion due to the common cold or influenza, with onset within less than 48 hours, with symptoms classified by the participant as moderate to severe on a 4-point scale (0 = no symptoms; 1 = mild symptoms; 2 = moderate symptoms; 3 = severe symptoms).\n  4. Must not have used any medication for symptomatic treatment of the condition.\n  5. Female participants without childbearing potential, defined as postmenopausal women (defined as 12 months or more of amenorrhea) or those who have undergone surgical sterilization\\*, OR female participants with reproductive potential who agree to use a reliable contraceptive method\\*\\*.\n\n     \\* Female sterilization (bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation performed at least 6 weeks before administration of the investigational product.\n\n     \\*\\* If the participant is of childbearing potential and decides to participate in the study, she must use or request that her partner use a reliable contraceptive method. Reliable contraception is defined as the use of at least one of the following: condoms, diaphragm, and\u002For hormonal contraceptive methods (estrogenic and\u002For progestogenic), including oral, vaginal, injectable, transdermal, implantable, and intrauterine devices. Only participants who explicitly declare no risk of pregnancy, either due to not engaging in sexual activity or engaging exclusively in non-reproductive practices, may participate without mandatory contraceptive use; for example: participants with a sterile or vasectomized partner (at least 6 months before screening), or total heterosexual abstinence.\n\n     Exclusion Criteria:\n* A positive response to any of the following criteria will exclude the participant from the study:\n\n  1. Participants with COVID-19, diagnosed by rapid antigen test and\u002For RT-PCR for SARS-CoV-2;\n  2. Previous contact with individuals diagnosed with COVID-19 within 14 days prior to screening;\n  3. Vaccination against influenza and\u002For COVID-19 within 7 days prior to the study;\n  4. Presence of gastrointestinal symptoms and\u002For dyspnea associated with cold or flu symptoms;\n  5. Clinical history consistent with bacterial upper respiratory tract infection requiring antibiotic therapy;\n  6. History of grade II or III septal deviation, nasal polyps, marked turbinate hypertrophy, adenoid hypertrophy, chronic sinusitis (or recent episode within the last 2 weeks), rhinitis (seasonal allergic, drug-induced, vasomotor, atrophic, or other), or other conditions causing nasal obstruction;\n  7. Diagnosis of: congenital glucose-6-phosphate dehydrogenase deficiency, prothrombin deficiency, gastroduodenal ulcer, hepatic porphyria, narrow-angle glaucoma, chronic nephritis, blood dyscrasias, asthma, chronic respiratory infection, chronic respiratory disease, severe cardiocirculatory conditions, or immunocompromised status;\n  8. History of hypersensitivity to analgesics, antirheumatic drugs, and\u002For alcoholic beverages;\n  9. Participants allergic to foods, hair dyes, and\u002For preservatives;\n  10. Participants dependent on decongestants (topical, nasal, or oral) or receiving allergen-specific immunotherapy;\n  11. Use of monoamine oxidase inhibitors (phenelzine, iproniazid, isocarboxazid, harmaline, nialamide, pargyline, selegiline, toloxatone, tranylcypromine, moclobemide), cyclosporine, chlorpromazine, barbiturates (phenobarbital, thiopental, methohexital, pentobarbital), hypnotics (triazolam, midazolam, oxazepam, chlordiazepoxide, clonazepam), narcotic analgesics (morphine, codeine, meperidine), sedatives, and\u002For tranquilizers;\n  12. History of alcoholism (average alcohol intake exceeding 3 standard drinks\\* in a single day or more than 7 drinks per week for women, and more than 4 drinks in a single day or more than 14 drinks per week for men);\n\n      * One standard drink is defined as: one can of regular beer (330 mL at 4%); one serving of distilled spirits (30 mL at 40%); one glass of wine or small glass of sherry (100 mL at 12% or 70 mL at 18%); one small glass of liqueur or similar (50 mL at 25%).\n  13. Pregnant or breastfeeding women, or those intending to become pregnant during the study period;\n  14. Participation in a clinical study within the last 12 months, at the investigator's discretion;\n  15. Any condition that, in the physician's judgment, may interfere with participation in the study.","60 Years",{"count":58,"type":21},620,"INTERVENTIONAL",[61],"PHASE3","Phase III clinical trial to evaluate the efficacy and safety of a fixed-dose combination of 1000 mg dipyrone monohydrate + 60 mg caffeine + 4 mg chlorpheniramine maleate in improving symptoms of the common cold and flu in adults.",[64,65,28],"Common Cold\u002FFlu","Nasal Congestion",[67,68,69,70,71,72,73,74],"nasal congestion","flu","cold","dipyrone","dipyrone monohydrate","caffeine","chlorpheniramine maleate","nasal obstruction","2026-06-15",{"date":77,"type":39},"2026-06-16",{"date":79,"type":39},"2026-05-08",{"date":81,"type":21},"2027-06-30",{"name":83,"class":84},"Brainfarma Industria Química e Farmacêutica S\u002FA","INDUSTRY",15,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":98,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":47},"100622142","evaluation-of-the-reliability-of-aar-as-an-independent-tool-for-surgical-indication-in-nasal-obstruction-100622142","NCT07379775","Evaluation of the Reliability of AAR as an Independent Tool for Surgical Indication in Nasal Obstruction","Evaluation of the Reliability of Anterior Active Rhinomanometry as an Independent Tool for Surgical Indication in Nasal Obstruction","RHINOVE","Inclusion Criteria:\n\n1. Patients aged 18 years or older with nasal obstruction (NO).\n2. Patients scheduled for surgery: septoplasty ± turbinoplasty ± rhinoplasty for nasal obstruction.\n3. Patients who have undergone a preoperative rhinomanometry assessment.\n4. Patients consented to participation\n\nExclusion Criteria:\n\n1. Nasal polyps.\n2. Chronic edematous-purulent rhinosinusitis (e.g., cystic fibrosis).\n3. Crusting rhinosinusitis (e.g., sarcoidosis, granulomatosis with polyangiitis \\[Wegener's\\]).\n4. Current or previously treated nasal or sinus tumors, or patients undergoing tumor work-up",{"count":95,"type":21},200,"Nasal obstruction (NO) affects \\~30% of the population and is a very common reason for consultation in otorhinolaryngology (ORL). In the majority of cases, the origin is inflammatory (allergic rhinitis and chronic rhinosinusitis) while in a minority of cases, the origin is structural, including septal deviation and inferior turbinate hypertrophy.\n\nNO significantly impairs patients' quality of life (QoL) and olfactory performance and also represents a contributing factor and comorbidity in asthma and obstructive sleep apnea syndrome. Several questionnaires for assessing QoL are available and routinely used to evaluate the impact of NO on patients : VAS, NOSE score, SNOT-22, and RhinoQOL score.\n\nSeveral objective functional methods for assessing NO have been described : acoustic rhinometry, nasal peak inspiratory flow, and active rhinomanometry. Rhinomanometry is a simple, non-invasive functional assessment method that allows for objective and quantitative analysis of nasal airway patency, thereby complementing the clinical and imaging evaluation of NO.\n\nIt has been recommended for the diagnosis of NO in cases of chronic rhinitis and chronic rhinosinusitis with nasal polyposis. Rhinomanometry comprises anterior active (AAR), posterior, and per-nasal rhinomanometry. AAR is the most commonly used method and is the only technique routinely available to clinicians. AAR provides precise information regarding the presence of nasal resistance responsible for NO. However, it should not be used as a standalone diagnostic tool due to its poor correlation with QoL questionnaires such as VAS and NOSE.\n\nWhether used alone or in combination with nasal decongestants, AAR provides a high predictive value for the outcomes of septoplasty and laser-assisted turbinoplasty.\n\nWhen surgery is indicated, its performance depends on:\n\n* type of obstruction or anatomical abnormality identified on clinical examination and\u002For computed tomography and\u002For AAR;\n* patient's symptoms and impairment of QoL NOSE and SNOT-22;\n* failure of a well-conducted first-line medical nasal treatment. Thus, in cases of septal deviation, septoplasty is performed; in cases of inferior turbinate mucosal hypertrophy with failure of medical treatment, turbinoplasty is performed; and in cases of mixed lesions, septo-turbinoplasty is performed.\n\nHowever, the concordance rate between the surgical technique indicated by clinical examination and computed tomography and the indications suggested by AAR is only 48.5%.",[28],{"date":77,"type":39},{"date":100,"type":39},"2026-01-27",{"date":102,"type":21},"2028-03",{"name":104,"class":46},"Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":113,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":116,"conditions":117,"keywords":122,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":47},"100637983","observational-study-of-rhinosedal-in-acute-nasal-obstruction-100637983","NCT07620522","Observational Study of RHINOSEDAL in Acute Nasal Obstruction","Prospective Multicenter Before-After Study in Children and Adults Treated for Acute Nasal Obstruction With RHINOSEDAL","RHINOSEDAL","Inclusion Criteria:\n\n* Age 8 years or older.\n* Acute nasal obstruction evolving for less than 48 hours associated with common cold, allergic or non-allergic rhinitis, or rhinosinusitis.\n* Baseline NOSE score \\>40\u002F100.\n* No warning signs such as pus, unilateral obstruction, bleeding, or pain.\n* RHINOSEDAL prescribed by the investigator.\n* Written informed consent signed.\n* Affiliated with a health insurance system.\n\nExclusion Criteria:\n\n* Known anatomical cause of chronic nasal congestion.\n* Corticosteroid use within the previous 2 days.\n* NSAID use within the previous 2 days.\n* Sympathomimetic use within the previous 2 days.\n* Nasal decongestant or nasal irrigation within the previous 2 days.\n* Antihistamines unless stable for more than 48 hours and maintained.\n* Contraindication listed in the RHINOSEDAL instructions for use.\n* Patient under legal protection.\n* Pregnant or breastfeeding women.","8 Years",{"count":115,"type":21},126,"This prospective, multicenter, national, observational, non-interventional post-market clinical follow-up study evaluates the performance and safety of RHINOSEDAL in children and adults presenting with acute nasal obstruction associated with common cold, allergic or non-allergic rhinitis, or rhinosinusitis. Patients prescribed RHINOSEDAL in routine care will be followed for 6 ±1 days using patient-reported outcome measures including the NOSE score.",[28,118,119,120,121],"Common Cold","Allergic Rhinitis","Non-allergic Rhinitis","Rhinosinusitis",[74,123,124,125,126,67,127,128,129,130],"NOSE score","rhinitis","rhinosinusitis","common cold","saline irrigation","medical device","PMCF","real-world evidence","NOT_YET_RECRUITING","2026-05-27",{"date":134,"type":39},"2026-06-02",{"date":136,"type":21},"2026-10-15",{"date":138,"type":21},"2027-12-31",{"name":140,"class":84},"Laboratoires Elerte",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":148,"sex":17,"minAge":18,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":59,"phases":152,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":47},"100509968","nasal-obstruction-and-olfactory-losses-100509968","NCT05920330","Nasal Obstruction and Olfactory Losses","Novel Mechanisms and Therapeutic Approaches for Nasal Obstruction and Olfactory Losses","Inclusion Criteria:\n\n1. Smell Loss complaints\n2. Nasal Obstruction\n\nExclusion Criteria:\n\n1. Congenital olfactory losses\n2. Nasal polyps, blocking the olfactory cleft\n3. Significant atrophy\n4. Cystic fibrosis\n5. Wegeners or any other connective tissue disorder\n6. Head trauma",true,"70 Years",{"count":151,"type":21},330,[153],"NA","About 13% of US adults, some 30 million people, suffer from nasal sinus disease. Although nasal obstruction and smell loss are two of the major symptoms of the disease that are crucial to disease management, currently there is a lack of clinical tools to effectively evaluate the mechanisms contributing to these symptoms. The proposed study aims to develop novel clinical tools to better evaluate and relieve patients' nasal obstructive symptoms and to enable patients and clinicians to make more informed, personalized decisions regarding treatment strategy.",[28],"2026-05-21",{"date":158,"type":39},"2026-05-26",{"date":160,"type":39},"2023-01-25",{"date":162,"type":21},"2028-12-31",{"name":164,"class":46},"Ohio State University",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":59,"phases":174,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":47},"100638123","active-vs-passive-vr-during-office-based-ent-procedures-100638123","NCT07599826","Active vs. Passive VR During Office-based ENT Procedures","Active vs. Passive Virtual Reality for Reducing Pain and Anxiety During Office-based ENT Procedures","Inclusion Criteria Active and Passive VR:\n\n* Individuals 18 years old and older are included\n* Individuals undergoing the following common office-based ENT procedures: turbinate reduction, nasal debridement, balloon sinuplasty, radiofrequency ablation (Rhineaer\u002FVivaer), nasal polypectomy, eustachian tube dilation, vocal fold injection, or subglottic steroid injection\n* Able to consent\n* English speaking\n\nExclusion Criteria Active VR:\n\n* History of neurologic or seizure disorder, developmental delay, uncorrected visual impairment, motion sickness, vertigo, or inability to use a handheld controller\n* Any records flagged \"break the glass\" or \"research opt out.\"\n\nExclusion Criteria Passive VR:\n\n* History of neurologic or seizure disorder, developmental delay, uncorrected visual impairment, motion sickness, or vertigo\n* Any records flagged \"break the glass\" or \"research opt out.\"",{"count":173,"type":21},132,[153],"The purpose of this research is to evaluate whether active virtual reality reduces pain and anxiety more effectively than passive virtual reality during office-based ENT procedures. The main procedures include exposure to virtual reality (passive calming scenery or interactive puzzle game) via Paperplane Therapeutics software with VR headset or glasses during common in-office ENT procedures, participant self-report surveys (GAD-7, PHQ-9, PEG, VAS, SUDS, Likert, experience questions), and physician post-procedure survey. The study will enroll individuals 18 years or older who are scheduled to undergo common office-based ENT procedures (turbinate reduction, nasal debridement, balloon sinuplasty, radiofrequency ablation, nasal polypectomy, eustachian tube dilation, vocal fold injection, or subglottic steroid injection) at Cedars Sinai.",[177,178,179,28,180,181,182,183],"Pain","Anxiety","Chronic Rhinosinusitis (CRS)","Nasal Polyp","Eustachian Tube Dysfunction","Dysphonia","Subglottic Stenosis (SGS)","2026-05-14",{"date":186,"type":39},"2026-05-20",{"date":188,"type":21},"2026-06",{"date":190,"type":21},"2027-12",{"name":192,"class":46},"Cedars-Sinai Medical Center",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":201,"enrollmentInfo":202,"targetDuration":4,"studyType":59,"phases":204,"briefSummary":205,"conditions":206,"keywords":211,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":4},"100636658","efficacy-and-safety-of-high-concentration-35-kda-hyaluronan-gel-for-chronic-nasopharyngitis-100636658","NCT07568548","Efficacy and Safety of High-Concentration 35 kDa Hyaluronan Gel for Chronic Nasopharyngitis","A Prospective, Single-Arm, Open-Label Pilot Clinical Study to Evaluate Efficacy and Safety of Topical 10% 35 kDa Hyaluronan (HA35) Gel for Ultra-Rapid Relief of Skin Pruritus","HA35","Inclusion Criteria:\n\n* Age 18-80 years, male or female\n* Clinically diagnosed with chronic rhinitis and chronic pharyngitis for ≥3 months\n* Baseline nasopharyngeal discomfort NRS score ≥4 points\n* Baseline posterior pharyngeal discomfort NRS score ≥4 points\n* Voluntary participation and signed written informed consent\n* Ability to complete symptom assessment independently\n\nExclusion Criteria:\n\n* Acute upper respiratory tract infection within 2 weeks\n* Use of antihistamines, intranasal corticosteroids, decongestants, or other nasal medications within 2 weeks prior to screening\n* History of nasal\u002Fsinus surgery within 6 months\n* Known hypersensitivity to hyaluronan or any gel ingredients\n* Pregnant or lactating women\n* Severe systemic diseases or malignant tumors","80 Years",{"count":203,"type":21},30,[153],"This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of nasopharyngeal administration of 13.6% high-concentration 35 kDa hyaluronan (HA35) care gel in subjects with chronic rhinitis and chronic pharyngitis. Eligible participants will receive the study gel twice daily for 10 consecutive days. The primary objectives are to assess rapid changes in nasopharyngeal discomfort, posterior pharyngeal discomfort, and nasal obstruction within 30 minutes after the first administration. Secondary objectives include evaluation of overall symptom improvement at day 10, changes in subjective mental clarity, and safety and tolerability throughout the treatment period. This is a minimal-risk, non-pharmacological supportive care intervention.",[207,208,209,210,28],"Chronic Rhinitis","Chronic Pharyngitis","Nasopharyngitis","Posterior Pharyngeal Inflammation",[212,213,199,214,207,208,65,215,216,217],"Hyaluronan","35 kDa Hyaluronan","Nasopharyngeal Care","Pharyngeal Discomfort","Non-pharmacological Intervention","Pilot Clinical Study","2026-05-05",{"date":79,"type":39},{"date":221,"type":21},"2026-05-01",{"date":223,"type":21},"2026-07-01",{"name":225,"class":84},"Nakhia Impex LLC",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":17,"minAge":234,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":250},"100560673","performance-and-safety-assessment-of-the-mechanical-decongestant-seawater-spray-enriched-with-essential-oils-from-laboratoires-gilbert-in-patient-with-acute-rhinitis-associated-with-nasal-obstruction-100560673","NCT06580210","Performance and Safety Assessment of the Mechanical Decongestant Seawater Spray Enriched With Essential Oils From Laboratoires Gilbert in Patient With Acute Rhinitis Associated With Nasal Obstruction","Prospective Multicenter Clinical Investigation to Evaluate the Performance and the Safety of the Mechanical Decongestant Seawater Spray Enriched With Essential Oils From Laboratoires Gilbert (DEMECA)","DEMECA","Inclusion Criteria:\n\n* 1\\. Patient ≥ 12 years,\n* 2\\. Patient with acute rhinitis associated with nasal obstruction during infectious episodes such as rhynopharyngitis (cold), rhinosinusitis, or during non-infectious episodes as allergic rhinitis,\n* 3\\. a. Informed adult patient who has given written consent prior to any study specific procedure,\n* b. Informed minor patients who has given assent and whose legal guardians have given written consent prior to any study specific procedure,\n* 4\\. Patient able to meet the study requirements (questionnaire completion),\n* 5\\. Patient affiliated to a social security scheme.\n\nExclusion Criteria:\n\n* 1\\. Patient who does not want to participate to the clinical investigation,\n* 2\\. Hypersensitivity to seawater and\u002For known allergies to any of the ingredients of the spray,\n* 3\\. A child with a history of febrile convulsions,\n* 4\\. Diseases leading to respiratory insufficiency,\n* 5\\. Patient suffering from nasal deformity or nasal polyps leading to chronic nasal obstruction,\n* 6\\. Patient on local ans systemic vasoconstrictors, local and systemic corticosteroids and antihistamines, non-steroidal anti-inflammatory (NSAIDs), antibiotics and local antiseptics,\n* 7\\. Concomitant use of other nasal sprays, essential oils for local nasal use and nsal cream or gel,\n* 8\\. Patient under guardianship, curatorship of safeguard of justice.","12 Years",{"count":236,"type":21},114,"The purpose of this post-market clinical investigation is to assess the performance and the safety of the mechanical decongestant seawater spray enriched with essential oils from Laboratoires Gilbert. The study will evaluate the results of the spray on the acute rhinitis with nasal obstruction over a 7 days period.",[239,28,121,240,119],"Acute Rhinitis","Rhinopharyngitis","2025-11-18",{"date":243,"type":39},"2025-11-21",{"date":245,"type":39},"2024-10-22",{"date":247,"type":21},"2026-06-07",{"name":249,"class":84},"Laboratoires Gilbert",3,{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":258,"enrollmentInfo":259,"targetDuration":4,"studyType":59,"phases":261,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":274},"100609471","acoustic-resonance-therapy-for-treating-empty-nose-syndrome-100609471","NCT07215013","Acoustic Resonance Therapy for Treating Empty Nose Syndrome","Acoustic Resonance Therapy for Treatment of Empty Nose Syndrome: A Prospective, Phase 2 Randomized Clinical Trial","Inclusion Criteria:\n\n* Documented case of Empty Nose Syndrome\n* Documented past turbinate reduction surgery\n\nExclusion Criteria:\n\n* Neurocognitive diagnosis\u002Fdecline","85 Years",{"count":260,"type":21},40,[153],"This study is to determine whether Acoustic Resonance Therapy (ART), an FDA-approved treatment for standard nasal obstruction, may be helpful in mitigating the debilitating symptoms of Empty Nose Syndrome (ENS), which includes an alternative form of nasal obstruction. ART is a non-invasive treatment that uses sound vibrations to improve nasal congestion and other sinus symptoms. ART works by delivering specific frequencies of sound to the sinonasal cavities (nose and sinuses). These vibrations cause the tissues in the sinuses to resonate, which can help break up mucus and clear blockages, reduce inflammation, and improve airflow.",[264,28],"Empty Nose Syndrome","2025-10-03",{"date":267,"type":39},"2025-10-10",{"date":269,"type":21},"2028-07",{"date":271,"type":21},"2030-07",{"name":273,"class":46},"Stanford University",2,{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":281,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":17,"minAge":234,"maxAge":4,"enrollmentInfo":283,"targetDuration":4,"studyType":59,"phases":285,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":296},"100477237","safety-and-performance-assessment-of-the-decongestant-seawater-spray-pocket-valve-enriched-with-essential-oils-in-patients-with-acute-rhinitis-associated-with-nasal-obstruction-devalpo-100477237","NCT05494346","Safety and Performance Assessment of the Decongestant Seawater Spray Pocket Valve Enriched With Essential Oils in Patients With Acute Rhinitis Associated With Nasal Obstruction: \"DEVALPO\"","Prospective Multicenter Clinical Investigation Evaluating the Performance and Safety of Gilbert Laboratories' Decongestant Seawater Spray Pocket Valve Enriched With Essential Oils","DEVALPO","Inclusion Criteria:\n\n* 1\\. Patient ≥ 12 years.\n* 2\\. Patient with acute rhinitis associated with nasal obstruction during infectious episodes such as rhinopharyngitis (cold), rhinosinusitis, or during non-infectious episodes such as allergic rhinitis.\n* 3\\. a. Informed adult patient who has given written consent prior to any study specific procedure. b. Informed minor patient who has given assent and whose legal guardians have given written consent prior to any study-specific procedure.\n* 4\\. Patient able to meet the study requirements for monitoring, spray use, and questionnaire completion.\n* 5\\. Patient affiliated to a social security scheme.\n\nExclusion Criteria:\n\n* 1\\. Pregnant and\u002For breastfeeding woman\n* 2\\. Hypersensitivity to seawater and\u002For known allergies to any of the ingredients of the spray.\n* 3\\. Diseases causing narrowing of the airways (e.g. asthma, chronic obstructive pulmonary disease (COPD)) and\u002For respiratory insufficiency.\n* 4\\. Patients with uncontrolled asthma (GINA score greater than or equal to 4)\n* 5\\. Patients undergoing allergy desensitization\n* 6\\. Patients suffering from chronic nasal obstruction due to a deformation of the nasal wall or nasal polyps. creams or gels.\n* 7\\. Patients taking local and systemic vasoconstrictors, corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics, and local antiseptics.\n* 8\\. Concomitant use of other nasal sprays, essential oils for local nasal use, creams, or gels for the nose.\n* 9\\. Patients under guardianship, conservatorship, or legal protection.",{"count":284,"type":21},101,[153],"The purpose of this pre-market clinical investigation is to assess the safety and the performance of decongestant seawater spray pocket valve enriched with essential oils by Gilbert Laboratories. The study will evaluate the results of acute rhinitis associated with nasal obstruction using the decongestant seawaterspray pocket valve enriched with essential oils over a 8 day period.",[239,28,121,240,119],"2025-09-19",{"date":290,"type":39},"2025-09-25",{"date":292,"type":39},"2023-06-23",{"date":294,"type":21},"2026-06-30",{"name":249,"class":84},5,{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":303,"eligibilityCriteria":304,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":305,"targetDuration":4,"studyType":59,"phases":307,"briefSummary":309,"conditions":310,"keywords":311,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":47},"100579885","phase-2-nasal-obstruction-with-oxymetazoline-and-corticosteroids-100579885","NCT06830109","Nasal Obstruction With Oxymetazoline and Corticosteroids","Nasal Obstruction Randomized Trial With Oxymetazoline and Corticosteroids","NORTOC","Inclusion Criteria:\n\n1. males and females ages 18 years or older\n2. have a history of nasal obstruction\n3. have failed a trial of topical steroids (that included at least 1 month of daily use)\n4. ability to read, write, and understand English\n5. either do not desire surgery or are poor surgical candidates due to medical comorbidities.\n6. Patients who have had prior use of oxymetazoline or other nasal decongestants are eligible for the study but must have stopped usage 4 weeks prior to randomization.\n\n   1. Must be willing to stop using any other nasal sprays, besides saline, and oral decongestants.\n\nExclusion Criteria:\n\n1. Any history of sinonasal mass\u002Ftumor\n2. Any history of nasal polyps\n3. a known history of chronic sinusitis\n4. an allergy to oxymetazoline\n5. or who have any medical contraindication to oxymetazoline use, such as pulmonary hypertension.",{"count":306,"type":21},80,[308],"PHASE2","This study aims to examine the efficacy and safety of commination oxymetazoline\u002Fintranasal steroids for long-term management of chronic nasal obstruction that is recalcitrant to the current standard of care. The investigators hypothesize that combination treatment with oxymetazoline and intranasal corticosteroid spray will provide a larger reduction in nasal obstruction than intranasal corticosteroid alone for patients suffering from chronic nasal obstruction, and there will not be occurrences of rhinitis medicamentosa.",[28],[312,313,314],"Oxymetazoline","Corticosteroids","Chronic rhinitis","2025-09-03",{"date":317,"type":39},"2025-09-11",{"date":319,"type":39},"2024-10-15",{"date":321,"type":21},"2026-12-30",{"name":323,"class":46},"Washington University School of Medicine",{"id":325,"slug":326,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":330,"eligibilityCriteria":331,"healthyVolunteers":148,"sex":17,"minAge":18,"maxAge":332,"enrollmentInfo":333,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":335,"conditions":336,"keywords":338,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":47},"100567597","diagnosis-of-respiratory-disorders-by-the-numerical-modeling-100567597","NCT06670261","Diagnosis of Respiratory Disorders by the Numerical Modeling.","JUNE Project: Does the Modeling of Nasal Airflows Improve the Pathophysiological Understanding and the Diagnosis of Functional Respiratory Disorders?","JUNE","Inclusion Criteria:\n\n* 18 years ≤ age \\\u003C 70 years\n* BMI \\\u003C 30 kg\u002Fm2\n* Subject or Patient of Caucasian ethnic origin or from the Mediterranean region.\n* Asymptomatic subject with or without a septal deviation without sinonasal disease with a NOSE score ≤ 7 Or Patient suffering from chronic nasal obstruction of morphological origin (symptomatic septal or nasoseptal deviation) requiring surgical management with a NOSE score ≥ 9\u002F20, without or .with sleep apnea with an Apnea-hypopnea index ≤ 20 with no other cause than this apnea syndrome\n\nExclusion Criteria:\n\n* Acute or chronic rhinosinusitis with or without polyps (except controlled allergic rhinitis)\n* Vasculitis\n* Empty nasal cavity syndrome\n* Septal perforations\n* History of nasal plastic surgery, sinonasal endoscopic surgery and cancer with head or neck radiotherapy\n* Uncontrolled bronchopulmonary pathology\n* Treatments with nasal vasomotor repercussions.","69 Years",{"count":334,"type":21},300,"Chronic Nasal obstruction (CNO) is not currently measurable objectively because clinicians use validated declarative self-questionnaires whose results are linked to the level of understanding, the acute or chronic clinical situation, fatigue, psychological state and the desired gain. Using numerical simulations of the passage of air in the nasal cavities determining specific airflow parameters, the respiratory comfort of healthy subjects and the CNO of patients treated for this pathology could be explained.",[28,337],"Deviated Nasal Septum",[339,340,341,342,343,344,345],"Numerical modeling","Fluid Dynamics","Computer simulation","Septoplasty","Nasal Air Flow","Sinonasal CT-Scan","Computational Fluid Dynamic Simulation","2025-04-18",{"date":348,"type":39},"2025-04-24",{"date":350,"type":39},"2024-07-09",{"date":352,"type":21},"2026-07-09",{"name":354,"class":46},"University Hospital, Bordeaux",{"id":356,"slug":357,"hasResults":11,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":362,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":364,"conditions":365,"keywords":367,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":47},"100356775","outcome-analysis-in-septorhinoplasty-100356775","NCT03925389","Outcome Analysis in Septorhinoplasty","Functional and Aesthetic Outcome Analysis in External Septorhinoplasty","Inclusion Criteria:\n\n* at least 18 years old\n* Patients eligible for external septorhinoplasty: patients seen in consultation because of nasal obstruction were evaluated. Patients who had symptoms of nasal obstruction for at least 1 year that were the result of an identifiable anatomical cause such as septal deviation, turbinate hypertrophy, internal valve collapse, or external valve collapse were included in the study.\n\nExclusion Criteria:\n\n* \\\u003C 18 years\n* mental or physical incapacity to answer the questionnaires\n* nasal fracture or surgery in the past year\n* nasal cocaine use in the past year",{"count":363,"type":21},750,"A prospective observational cohort study that measures pre- and postoperative outcome of septorhinoplasty by means of patient-related outcome measures (PROMS: NOSE, FACE-Q, Utrecht Questionnaire, SCHNOS and BDDQ-AS) as well as with functional tests (NAR, AR, PNIF).",[27,28,366],"Esthetics",[368,369,370,371,372,373,366],"Nasal function","Septorhinoplasty","Patient-reported outcome","Rhinomanometry","Acoustic Rhinometry","Peak Nasal Inspiratory Flow","2025-03-24",{"date":376,"type":39},"2025-03-27",{"date":378,"type":39},"2019-05-07",{"date":380,"type":21},"2025-12-10",{"name":382,"class":46},"FRANK DECLAU",{"id":384,"slug":385,"hasResults":11,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":148,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":390,"targetDuration":4,"studyType":59,"phases":392,"briefSummary":393,"conditions":394,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":250},"100461376","does-batten-grafting-improve-nasal-outcomes-in-septoplasty-and-turbinate-reduction-100461376","NCT05287841","Does Batten Grafting Improve Nasal Outcomes in Septoplasty and Turbinate Reduction?","Does the Addition of Batten Grafting Improve Nasal Outcomes in Patients Undergoing Septoplasty and Turbinate Reduction? A Pragmatic Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients should satisfy all the following criteria to be considered eligible for randomization:\n\n  1. Be age 18 or above\n  2. Able to provide written informed consent\n  3. Have an indication for batten graft, septoplasty and turbinate reduction according to prevailing surgical practices.\n\n  \u003C!-- -->\n\n  1. Septal deviation must be present on direct or endoscopic examination\n  2. Inferior turbinate hypertrophy must be present, direct examination or endoscopic examination\n  3. Collapse of external nasal valve and\u002For lateral motion instability must be documented\n\n  \u003C!-- -->\n\n  1. The ENV maye be assessed clinically by observing the alar collapse at baseline or with forced inspiration, Modified cottle may also be performed.\n\nIn all patients, endoscopic examination should document that the (a) septal deviation, (b) turbinate hypertrophy, and (c) external nasal valve collapse are the primary contributing factors of obstructed breathing.\n\nExclusion Criteria:\n\n1. Septal perforation\n2. History of previous functional rhinoplasty or sinus or septal surgery\n3. Patients who are selected for concurrent aesthetic\u002Fcosmetic rhinoplasty\n4. Untreated allergic rhinitis or allergic rhinitis unresponsive to medical management\n5. Patients who have concurrent sinus surgery or polyp removal or concha bullosa resection",{"count":391,"type":21},96,[153],"The objective of this study is to compare the effectiveness of batten grafts plus septoplasty and turbinate reduction (intervention arm) compared to septoplasty and turbinate reduction alone (control arm), both in terms of subjective and objective assessments.",[28,395,119,396,397],"Septal Defect","Nasal Polyps","Nasal Valve Collapse","2024-09-18",{"date":400,"type":39},"2024-09-20",{"date":402,"type":39},"2021-04-30",{"date":404,"type":21},"2025-06-15",{"name":406,"class":46},"Northwell Health"]